PPGN.SW stock rises 10.07% to CHF31.15 on strong 2025 results (SIX): small upside ahead
PPGN.SW stock jumped 10.07% to CHF31.15 at market close on 19 Jan 2026 after PolyPeptide Group AG reported preliminary 2025 results showing ~EUR389.00 million revenue and an 11–12% EBITDA margin. The move came on above-average volume of 124,026 shares on the SIX Swiss Exchange and follows sustained demand for metabolic therapeutics. We assess valuation, technicals and near-term upside using company metrics, sector context and Meyka AI-powered market analysis platform outputs to frame realistic price targets and risks.
PPGN.SW stock: Market reaction and news drivers
The stock rise reflects strong preliminary 2025 figures: revenue ~EUR389.00 million (+15.60%) and an EBITDA margin near 11–12%, according to company updates reported today. Trading volume was 124,026 versus a 50-day average of 47,655, signaling conviction among buyers. Nasdaq/RTTNews report and regional coverage noted capex of ~EUR100.00 million and EUR75.00 million cash on hand, supporting operational spending and expansions.
PPGN.SW stock: Valuation and key financial metrics
At CHF31.15 the company trades with a price-to-sales ~3.00 and price-to-book ~3.36, while TTM EPS is -0.97 and P/E reads -32.11, reflecting still-negative earnings. Free cash flow yield is 2.94% and debt-to-equity is 0.30, giving a manageable leverage profile. Revenue per share TTM is 11.12 and book value per share is 9.98, which suggest the market is pricing growth and margin recovery into the current level.
PPGN.SW stock: Technicals and trading signals
Momentum indicators show a short-term bullish bias: RSI 67.74 and MACD 0.51 (signal 0.27) with a strong daily range CHF28.80–CHF31.20. The 50-day average is CHF25.22 and the 200-day average is CHF22.97, indicating the recent rally has moved price well above trend. On-balance volume and relative volume (2.60x) confirm institutional interest, but CCI and stochastic readings suggest near-term overbought conditions.
PPGN.SW stock: Meyka AI grade and analyst framing
Meyka AI rates PPGN.SW with a score out of 100: 65.74 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The model highlights improving revenue growth and EBITDA margin expansion but notes negative EPS and elevated capex. These grades are model outputs, not guaranteed, and are not financial advice.
PPGN.SW stock: Forecasts, price targets and scenarios
Meyka AI’s forecast model projects yearly CHF31.67, 3-year CHF32.14, and 5-year CHF32.92. Versus the current CHF31.15, that implies an upside of 1.67%, 3.17%, and 5.68% respectively. A pragmatic set of targets: a near-term base CHF33.00 (up 5.92%), bull CHF36.00 (up 15.63%), and bear CHF28.00 (down -10.14%). Forecasts are model-based projections and not guarantees.
PPGN.SW stock: Risks and sector context
PolyPeptide sits in the Healthcare sector (Drug Manufacturers – Specialty & Generic) where peers trade at higher average margins and ROE; sector YTD strength has been +5.44%. Key risks include execution on large capex programs, extended inventory days (inventory days 175.83) and ongoing negative EPS. Upside catalysts include continued margin improvement, stronger metabolic therapeutics demand and successful capacity utilisation.
Final Thoughts
PPGN.SW stock moved sharply higher on 19 Jan 2026 after preliminary 2025 results showed revenue growth and margin recovery; the move tested the year high CHF31.20 and closed at CHF31.15 on notable volume. Valuation mixes recovery expectations with legacy losses: P/S ~3.00, P/B ~3.36, EPS -0.97 and free cash flow yield 2.94%. Technicals are bullish but near-term overbought. Meyka AI’s model shows limited upside in the near term (yearly target CHF31.67, implied +1.67%), while a base case target of CHF33.00 assumes steady margin gains and demand stability. Investors should weigh the company’s expanding EBITDA margin and strong revenue growth against negative earnings, sizeable capex and inventory cycle risk. For active traders the recent breakout offers momentum opportunities, while longer-term investors may prefer to wait for consistent EPS improvement or clearer guidance at the earnings announcement on 2026-03-12. See full data and model notes on the Meyka stock page for PPGN.SW: Meyka PPGN.SW page.
FAQs
Why did PPGN.SW stock spike today?
The stock rose 10.07% after PolyPeptide reported preliminary 2025 revenue of ~EUR389.00 million and an improved 11–12% EBITDA margin, plus capex and cash updates that reassured investors. See reporting at [Nasdaq/RTTNews](https://www.nasdaq.com/articles/polypeptide-reports-strong-prelim.
What is Meyka AI’s view on PPGN.SW stock?
Meyka AI rates PPGN.SW 65.74 (Grade B, HOLD), citing revenue growth, margin improvement and manageable debt but noting negative EPS and high capex. The grade is model-based and not financial advice.
What near-term price target should investors use for PPGN.SW stock?
A pragmatic near-term base target is CHF33.00 (approx +5.92%). Bull and bear scenarios range CHF36.00 and CHF28.00 respectively. Use targets alongside cash flow, guidance and upcoming earnings on 2026-03-12.
How do valuation metrics look for PPGN.SW stock?
At CHF31.15 valuations show P/S ~3.00, P/B ~3.36, negative P/E (-32.11) and free cash flow yield 2.94%, signalling priced-in recovery expectations but ongoing profitability risks.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
